Levi & Korsinsky notifies investors that it has commenced an investigation into Zoetis Inc. (NYSE: ZTS) concerning potential violations of the federal securities laws.
Zoetis reported Q1 2026 revenue that missed analyst consensus estimates, driven by weaker-than-expected U.S. companion animal sales and increased competitive pressure across its dermatology and pain franchises. The company simultaneously reduced its FY 2026 organic operational revenue growth guidance from the previously issued range of 3% to 5%, citing soft U.S. pet-care demand and macro-economic headwinds. Shares closed down approximately 21.50% on heavy volume. The magnitude of the market reaction reflected the gap between management's prior outlook and reported results. On the Q4 2025 earnings call in February 2026, CEO Kristin Peck had guided investors to expect 3% to 5% organic operational revenue growth for fiscal 2026. CFO Wetteny Joseph had also acknowledged that Q4 2025 international revenue included an approximate 2.5% to 3.5% one-time sales acceleration that the company did not expect to recur -- a detail that made the subsequent miss and guidance cut even more significant to investors pricing the stock on forward expectations.
If you suffered a loss on your Zoetis Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





